Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) will announce its earnings results before the market opens on Wednesday, August 14th. Analysts expect the company to announce earnings of ($1.06) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.
Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($1.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.67). On average, analysts expect Outlook Therapeutics to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Outlook Therapeutics Trading Up 2.3 %
OTLK opened at $7.51 on Tuesday. Outlook Therapeutics has a 1-year low of $4.00 and a 1-year high of $32.00. The stock’s fifty day simple moving average is $7.63 and its 200 day simple moving average is $8.08. The stock has a market cap of $175.78 million, a PE ratio of -0.66 and a beta of 0.71.
Wall Street Analysts Forecast Growth
Get Our Latest Report on Outlook Therapeutics
About Outlook Therapeutics
Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Further Reading
- Five stocks we like better than Outlook Therapeutics
- Stock Market Sectors: What Are They and How Many Are There?
- How to Invest in Silver: A Beginner’s Guide
- 3 Warren Buffett Stocks to Buy Now
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- How to Use the MarketBeat Stock Screener
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.